An affinity selection-mass spectrometry method for the identification of small molecule ligands from self-encoded combinatorial libraries -: Discovery of a novel antagonist of E-coli dihydrofolate reductase

被引:97
|
作者
Annis, DA
Athanasopoulos, J
Curran, PJ
Felsch, JS
Kalghatgi, K
Lee, WH
Nash, HM
Orminati, JPA
Rosner, KE
Shipps, GW
Thaddupathy, GRA
Tyler, AN
Vilenchik, L
Wagner, CR
Wintner, EA
机构
[1] NeoGenesis Pharmaceut, Cambridge, MA 02139 USA
[2] Univ Minnesota, Coll Pharm, Dept Med Chem, Minneapolis, MN 55455 USA
关键词
affinity selection-mass spectrometry; combinatorial chemistry; multidimensional chromatography;
D O I
10.1016/j.ijms.2003.11.022
中图分类号
O64 [物理化学(理论化学)、化学物理学]; O56 [分子物理学、原子物理学];
学科分类号
070203 ; 070304 ; 081704 ; 1406 ;
摘要
The NeoGenesis Automated Ligand Identification System (ALIS), an affinity selection-mass spectrometry (AS-MS) process consisting of a rapid size-exclusion chromatography stage integrated with reverse-phase chromatography, electrospray mass spectrometry, and novel data searching algorithms, was used to screen mass-encoded, 2500-member combinatorial libraries, leading to the discovery of a novel, bioactive ligand for the anti-infective target Escherichia coli dihydrofolate reductase (DHFR). Synthesis of the mass-encoded, ligand-containing library, discussion of the deconvolution process for verifying the structure of the ligand through independent synthesis and screening in a small mixture (sub-library) format, and ALIS-MS/MS techniques to assign its regioisomeric connectivity are presented. ALIS-based competition experiments between the newly discovered ligand and other, known DHFR ligands, and biological activity assessments with stereo- and regioisomers of the hit compound confirm its DHFR-specific biological activity. The method described requires no foreknowledge of the structure or biochemistry of the protein target, consumes less than 1 mug protein to screen >2500 compounds in a single experiment, and enables screening of >250,000 compounds per system per day. These advantages highlight the potential of the ALIS method for drug discovery against genomic targets with unknown biological function, as well as validated targets for which traditional discovery efforts have failed. (C) 2004 Elsevier B.V. All rights reserved.
引用
收藏
页码:77 / 83
页数:7
相关论文
共 1 条
  • [1] Affinity selection-mass spectrometry for the discovery of pharmacologically active compounds from combinatorial libraries and natural products
    Muchiri, Ruth N.
    van Breemen, Richard B.
    JOURNAL OF MASS SPECTROMETRY, 2021, 56 (05):